(1) 肿瘤免疫微环境
(2) 表观遗传调控
(3) 脂代谢调控

（1）国家自然科学基金委员会，青年科学基金项目，82203820，JARID2协同CRL4B复合物促进乳腺癌发生发展与转移的分子机制研究，2023-01-01至2025-12-31，30万元，结题，主持
（2）中国博士后科学基金，第71批面上项目，2022M710454，JARID2 协同 CRL4B 复合物调控乳腺癌组织Th17/Treg失调的表观遗传学机制研究，2023-01-01至2024-12-31，8万元，结题，主持

1.Yunkai Yang#, Tianyang Gao#, Baowen Yuan#, Xinhui Hao, Miaomiao Huo, Ting Hu, Tianyu Ma, Min Zhang, Die Zhang, Xu Teng, Hefen Yu, Wei Huang*, Jingyao Zhang*, Yan Wang*, KDM5B cooperates with CRL4B complex to promote the tumorigenesis of ER+ breast cancer via regulating cholesterol metabolism. Cell Death & Disease, 2026, 17(1):207. (IF: 12.2)
2.Yunkai Yang, Xinhui Hao, Jingyao Zhang, Tianyang Gao, Miaomiao Huo, Wei Liu, Ting Hu, Tianyu Ma, Baowen Yuan, Min Zhang, Xu Teng, Hefen Yu, Wei Huang, Yan Wang*, The E3 ligase TRIM22 functions as a tumor suppressor in breast cancer by targeting CCS for proteasomal degradation to inhibit STAT3 signaling. Cancer Letters, 2024, 600:217157. (IF: 9.1)
3.Wei Liu#, Yi Zeng#, Xinhui Hao, Xin Wang, Jiaxiang Liu, Tianyang Gao, Mengdi Wang, Jingyao Zhang, Miaomiao Huo, Ting Hu, Tianyu Ma, Die Zhang, Xu Teng, Hefen Yu, Min Zhang, Baowen Yuan, Wei Huang*, Yunkai Yang*, Yan Wang*, JARID2 coordinates with the NuRD complex to facilitate breast tumorigenesis through response to adipocyte-derived leptin. Cancer Communications, 2023, 43(10):1117-1142. (IF: 16.2)
4.Yunkai Yang#, Min Zhang#, Yan Wang*, The roles of histone modifications in tumorigenesis and associated inhibitors in cancer therapy. Journal of the National Cancer Center, 2022, 2(4):277-290.
5.Yunkai Yang, Yan Wang*, Role of Epigenetic Regulation in Plasticity of Tumor Immune Microenvironment. Frontiers in Immunology, 2021, 12:640369. (IF: 7.561)
6.Yunkai Yang, Xiaohan Guo, Bo Hu, Peng He, Xiaowu Jiang, Zuohuan Wang, Huaxing Zhu, Lina Hu*, Minghua Yu*, Meiqing Feng*, Generated SecPen_NY-ESO-1_ubiquitin-pulsed dendritic cell cancer vaccine elicits stronger and specific T cell immune responses. Acta Pharmaceutica Sinica B, 2021, 11(2):476-487. (IF: 11.614)